Glenmark Chief on Cracking the Multi-Specific Code
Glenmark Chairman and Managing Director Glen Saldanha joins Vikas Dandekar and Rica Bhattacharyya to discuss the company’s 25-year innovation bet, and why it’s finally paying off. At the center is ISB2001, a tri-specific antibody partnered with AbbVie, born out of Glenmark’s IGI platform after fifteen years of R&D.…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from The Morning Brief
See all episodes →
Similar episodes from other shows
More like The Morning Brief →
How Wockhardt solved a problem Indian pharma couldn't
The price drop in weight-loss drugs Indian pharma can’t handle
Indian pharma: lofty aims in the midst of chaos
#041 Prices of Expensive Diabetes Drugs Are Falling And More Manufacturers Are Rushing In
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.